The Next Generation Biotech Media
20191216-1222 Takeda, Turnstone Biologics to develop novel viral immunotherapies On December 20th, Turnstone Biologics, a U.S.-based immunotherapy-developing company, announced a strategic collaboration with Japan-based Takeda Pharmaceutical Company, to develop a …
Read More
The rise of South Korean biotechnology is a recent one and goes back to the late 1990s when the first South Korean biotech company, Macrogen Inc. was formed. Since then, …
Read More
Can the convergence of Taiwan’s Biomedical and ICT Industry help Taiwan grow into a leader in the digital health market？ Taiwan is a world-renowned leader in the global information communication …
Read More
20191209-1215 Biocon and Equillium Expand Collaboration to Australia, NZ India headquartered Biocon Ltd and US based Equillium Inc., announced on December 13th that they have expanded collaboration and license agreement …
Read More
The Lifestyle Medicine Summit 2019 invited Dr. Sara Gottfried from Harvard Medical School, Dr. Myles Spar, an authority in male’s integrative medicine in the U.S., Dr. Kuei-Liang Wang, the Founder …
Read More
20191202-1208 Japan’s Astellas to Acquire Audentes for $3 Billion Gene therapies are one of the emerging areas in drug research globally. Japan’s Astellas Pharma Inc is now buying U.S. drugmaker …
Read More
20191117-1123 Innovative PD-1 Inhibitor Tyvyt® (Sintilimab) Now Included in the New Catalogue of National Reimbursement Drug List (NRDL) On November 28, Innovent Biologics, Inc. and Eli Lilly and Company jointly …
Read More
Amarin, a pharmaceutical company developing therapeutics to improve cardiovascular health, and its latest product Vascepa approaches an approval for expanding the application of the treatment of cardiovascular (CV) patients to …
Read More
20191117-1123 Japan Grants Orphan Drug Designation to Merck’s investigational therapy Tepotinib According to estimations, the incidence of cancer has increased at a rapid pace and hence, it has ascended to …
Read More
By Rajaneesh K. Gopinath, Ph.D. Alnylam Pharmaceutical’s GIVLAARI™ (givosiran) became the second-ever RNA interference-based drug to bag the FDA nod. The RNA interference (RNAi) phenomenon discovered by Andrew Fire and …
Read More